View in EDS HTML Full Text PDF Full Text

Nanoparticle platform preferentially targeting liver sinusoidal endothelial cells induces tolerance in CD4+ T cell-mediated disease models.

Saved in:
Bibliographic Details
Title: Nanoparticle platform preferentially targeting liver sinusoidal endothelial cells induces tolerance in CD4+ T cell-mediated disease models.
Authors: Wang SH; Department of Clinical Development, Topas Therapeutics GmbH, Hamburg, Germany., Serr I; Research Unit Type 1 Diabetes Immunology, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany., Digigow R; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Metzler B; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany., Surnov A; Research Unit Type 1 Diabetes Immunology, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany., Gottwick C; Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Alsamman M; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany., Krzikalla D; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany., Heine M; Department of Biochemistry and Molecular Cell Biology (N30), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Zahlten M; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany., Widera A; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany., Mungalpara D; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Şeleci M; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Fanzutti M; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Marques Mesquita LM; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Vocaturo AL; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Herkel J; Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.; Hamburg Centre for Translational Immunology (HCTI), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Carambia A; Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Schröter C; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Sarko D; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Pohlner J; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany., Daniel C; Research Unit Type 1 Diabetes Immunology, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany.; Division of Clinical Pharmacology, Department of Medicine IV, Ludwig Maximilian University of Munich, Munich, Germany., de Min C; Department of Clinical Development, Topas Therapeutics GmbH, Hamburg, Germany., Fleischer S; Department of Clinical Development, Topas Therapeutics GmbH, Hamburg, Germany.
Source: Frontiers in immunology [Front Immunol] 2025 Mar 17; Vol. 16, pp. 1542380. Date of Electronic Publication: 2025 Mar 17 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40165970
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Nanoparticle platform preferentially targeting liver sinusoidal endothelial cells induces tolerance in CD4+ T cell-mediated disease models.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wang+SH%22">Wang SH</searchLink>; Department of Clinical Development, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Serr+I%22">Serr I</searchLink>; Research Unit Type 1 Diabetes Immunology, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany.<br /><searchLink fieldCode="AU" term="%22Digigow+R%22">Digigow R</searchLink>; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Metzler+B%22">Metzler B</searchLink>; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Surnov+A%22">Surnov A</searchLink>; Research Unit Type 1 Diabetes Immunology, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany.<br /><searchLink fieldCode="AU" term="%22Gottwick+C%22">Gottwick C</searchLink>; Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Alsamman+M%22">Alsamman M</searchLink>; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Krzikalla+D%22">Krzikalla D</searchLink>; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Heine+M%22">Heine M</searchLink>; Department of Biochemistry and Molecular Cell Biology (N30), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Zahlten+M%22">Zahlten M</searchLink>; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Widera+A%22">Widera A</searchLink>; Department of Preclinical Development, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Mungalpara+D%22">Mungalpara D</searchLink>; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Şeleci+M%22">Şeleci M</searchLink>; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Fanzutti+M%22">Fanzutti M</searchLink>; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Marques+Mesquita+LM%22">Marques Mesquita LM</searchLink>; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Vocaturo+AL%22">Vocaturo AL</searchLink>; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Herkel+J%22">Herkel J</searchLink>; Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.; Hamburg Centre for Translational Immunology (HCTI), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Carambia+A%22">Carambia A</searchLink>; Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Schröter+C%22">Schröter C</searchLink>; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Sarko+D%22">Sarko D</searchLink>; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Pohlner+J%22">Pohlner J</searchLink>; Department of Chemistry, Manufacturing & Controls, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Daniel+C%22">Daniel C</searchLink>; Research Unit Type 1 Diabetes Immunology, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.; German Center for Diabetes Research (DZD), Neuherberg, Germany.; Division of Clinical Pharmacology, Department of Medicine IV, Ludwig Maximilian University of Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22de+Min+C%22">de Min C</searchLink>; Department of Clinical Development, Topas Therapeutics GmbH, Hamburg, Germany.<br /><searchLink fieldCode="AU" term="%22Fleischer+S%22">Fleischer S</searchLink>; Department of Clinical Development, Topas Therapeutics GmbH, Hamburg, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2025 Mar 17; Vol. 16, pp. 1542380. <i>Date of Electronic Publication: </i>2025 Mar 17 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40165970
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2025.1542380
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1542380
    Titles:
      – TitleFull: Nanoparticle platform preferentially targeting liver sinusoidal endothelial cells induces tolerance in CD4+ T cell-mediated disease models.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wang SH
      – PersonEntity:
          Name:
            NameFull: Serr I
      – PersonEntity:
          Name:
            NameFull: Digigow R
      – PersonEntity:
          Name:
            NameFull: Metzler B
      – PersonEntity:
          Name:
            NameFull: Surnov A
      – PersonEntity:
          Name:
            NameFull: Gottwick C
      – PersonEntity:
          Name:
            NameFull: Alsamman M
      – PersonEntity:
          Name:
            NameFull: Krzikalla D
      – PersonEntity:
          Name:
            NameFull: Heine M
      – PersonEntity:
          Name:
            NameFull: Zahlten M
      – PersonEntity:
          Name:
            NameFull: Widera A
      – PersonEntity:
          Name:
            NameFull: Mungalpara D
      – PersonEntity:
          Name:
            NameFull: Şeleci M
      – PersonEntity:
          Name:
            NameFull: Fanzutti M
      – PersonEntity:
          Name:
            NameFull: Marques Mesquita LM
      – PersonEntity:
          Name:
            NameFull: Vocaturo AL
      – PersonEntity:
          Name:
            NameFull: Herkel J
      – PersonEntity:
          Name:
            NameFull: Carambia A
      – PersonEntity:
          Name:
            NameFull: Schröter C
      – PersonEntity:
          Name:
            NameFull: Sarko D
      – PersonEntity:
          Name:
            NameFull: Pohlner J
      – PersonEntity:
          Name:
            NameFull: Daniel C
      – PersonEntity:
          Name:
            NameFull: de Min C
      – PersonEntity:
          Name:
            NameFull: Fleischer S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 17
              M: 03
              Text: 2025 Mar 17
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1